Relationship between pretreatment anxiety/depression and functional outcomes in prostate cancer treatment

Elliott J Druten, BS¹, Will P Hoover, BS¹, Jacob Bardell, MD³, Haris Sharieff, BS¹, Dustin Dang, BS¹, Chase Gaddis, BS², Jonathan Heinlen, MD⁴ ¹ University of Oklahoma College of Medicine, Oklahoma City, Oklahoma ² OU-TU School of Community Medicine, Tulsa, Oklahoma ³ Department of Urology, University of Kansas Health System, Kansas City, Kansas ⁴ Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Background

- Prostate cancer patients often experience higher levels of anxiety and depression than the general population.
- Depression is recognized as a factor in prostate cancer progression and potential clinical deterioration.
- While anxiety and depression are prevalent throughout prostate cancer treatment, their specific influence on clinical outcomes remains underexplored.
- This study, employing the Patient Health Questionnaire-9 (PHQ-9), aims to clarify the connection between pretreatment anxiety/depression and subsequent clinical outcomes in prostate cancer treatment.

Purpose


• To evaluate the relationship between pretreatment anxiety/depression and urinary incontinence in prostate cancer patients.


Methods

- We retrospectively reviewed patients diagnosed with prostate cancer at our institution between 2016 and 2021.
- Inclusion criteria required pre-treatment PHQ-9 assessments, while exclusions covered mortality, incomplete PHQ-9s, and lost follow-ups.
- We examined outcomes, including post-treatment incontinence and erectile dysfunction, at four intervals: pre-treatment baseline, first posttreatment visit, six months post-treatment, and oneyear post-treatment.

Methods (Cont.)

- Incontinence was measured by daily urinary pad use (0, 1, 2, 3-4, 5-6, 7+), and erectile dysfunction referred to as an inability to engage in intercourse.
- We considered cancer staging at diagnosis and various treatment modalities, including active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, biologic therapy, and bisphosphonate therapy.
- Statistical analysis relied on the Chi-square test and Fisher's Exact Test.





- Our study involved 489 patients with pre-treatment PHQ-9 results. Mean age was 64.45 years (SD 8.12), with 87% Caucasian, 13% African Americans, and 1% Asians.
- At baseline, 80% had minimal depression, while 12%, 4%, 3%, and 1% experienced mild, moderate, moderately severe, or severe depression, respectively.



- months (p=0.019).

- mild depression.



Results (Cont.)

The percentage of patients with erectile dysfunction at first office visit, six months, and twelve months was 66% (p=0.612), 65% (p=0.520), and 61% (p=0.607). For incontinence, these percentages were 35% (p=0.086), 26% (p=0.272), and 19% (p=0.270). • There were significant differences in the prevalence of incontinence between minimal to mild depression and moderate to severe depression at the first post-treatment appointment (p=0.026), six months (p=0.049), and twelve

Discussion/Conclusion

• There are no differences in continence vs incontinence by depression at baseline, or in erectile dysfunction by depression at baseline. • There is a clear association between moderate to severe depression with post-treatment incontinence compared to patients with minimal to

• These findings underscore the importance of addressing mental health in the care of prostate cancer patients to potentially improve their postoperative functional outcomes.

• Further research is needed to better understand and address these associations.

